MedPath
FDA Approval

Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide

June 6, 2023

HUMAN PRESCRIPTION DRUG LABEL

Brompheniramine(2 mg in 5 mL)
Pseudoephedrine(30 mg in 5 mL)
Dextromethorphan(10 mg in 5 mL)

Manufacturing Establishments (1)

A-S Medication Solutions

A-S Medication Solutions

830016429

Products (1)

Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide

50090-5625

ANDA205292

ANDA (C73584)

ORAL

November 22, 2021

Code: IXA7C9ZN03Class: ACTIBQuantity: 2 mg in 5 mL
Code: 6V9V2RYJ8NClass: ACTIBQuantity: 30 mg in 5 mL
Code: 9D2RTI9KYHClass: ACTIBQuantity: 10 mg in 5 mL
ALCOHOLInactive
Code: 3K9958V90MClass: IACT
ANHYDROUS CITRIC ACIDInactive
Code: XF417D3PSLClass: IACT
METHYLPARABENInactive
Code: A2I8C7HI9TClass: IACT
PROPYLENE GLYCOLInactive
Code: 6DC9Q167V3Class: IACT
WATERInactive
Code: 059QF0KO0RClass: IACT
GLYCERINInactive
Code: PDC6A3C0OXClass: IACT
SUCROSEInactive
Code: C151H8M554Class: IACT
SODIUM BENZOATEInactive
Code: OJ245FE5EUClass: IACT
FD&C RED NO. 40Inactive
Code: WZB9127XOAClass: IACT
SODIUM CITRATE, UNSPECIFIED FORMInactive
Code: 1Q73Q2JULRClass: IACT

Drug Labeling Information

PRECAUTIONS SECTION

PRECAUTIONS

General

Because of its antihistamine component, Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Syrup should be used with caution in patients with a history of bronchial asthma, narrow angle glaucoma, gastrointestinal obstruction, or urinary bladder neck obstruction. Because of its sympathomimetic component, Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Syrup should be used with caution in patients with diabetes, hypertension, heart disease, or thyroid disease.

Information for Patients

Patients should be warned about engaging in activities requiring mental alertness, such as driving a car or operating dangerous machinery.

Drug Interactions

Monoamine oxidase (MAO) inhibitors

Hyperpyrexia, hypotension, and death have been reported coincident with the coadministration of MAO inhibitors and products containing dextromethorphan. In addition, MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines and may enhance the effect of pseudoephedrine. Concomitant administration of Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Syrup and MAO inhibitors should be avoided (seeCONTRAINDICATIONS).

Central Nervous System (CNS) depressants

Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc.).

Antihypertensive drugs

Sympathomimetic may reduce the effects of antihypertensive drugs.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Animal studies of Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Syrup to assess the carcinogenic and mutagenic potential or the effect on fertility have not been performed.

Pregnancy

Teratogenic Effects

Pregnancy Category C

Animal reproduction studies have not been conducted with Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Syrup. It is also not known whether Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Syrup can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. It should be given to a pregnant woman only if clearly needed.

Reproduction studies of brompheniramine maleate (a component of Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Syrup) in rats and mice at doses up to 16 times the maximum human doses have revealed no evidence of impaired fertility or harm to the fetus.

Nursing Mothers

Because of the higher risk of intolerance of antihistamines in small infants generally, and in newborns and prematures in particular, Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Syrup is contraindicated in nursing mothers.

Pediatric Use

Safety and effectiveness in pediatric patients below the age of 6 months have not been established (seeDOSAGE AND ADMINISTRATION).


STORAGE AND HANDLING SECTION

RECOMMENDED STORAGE

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

Keep Tightly Closed

Dispense in a tight, light-resistant container as defined in the USP.

Rx Only

Manufactured By Padagis

Minneapolis, MN 55427

2204460

0U426 RC M F1

Rev 11-21 A


© Copyright 2025. All Rights Reserved by MedPath